Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338046 | 0.85 | TRPA1 (0.45) | KMT2ATRPA1TSHRHSD17B10AAK1 | |
| SCHEMBL595185 | 0.80 | L3MBTL1 (0.34) | KMT2AMAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL594117 | 0.77 | CYP17A1 (0.40) | AAK1CA1CA2 | |
| SCHEMBL1337974 | 0.76 | FOLH1 (0.45) | KMT2ATRPA1TSHRHSD17B10AAK1 | |
| SCHEMBL593784 | 0.75 | AAK1 (0.33) | AAK1 | |
| SCHEMBL593785 | 0.75 | AAK1 (0.33) | AAK1 | |
| SCHEMBL595627 | 0.75 | AAK1 (0.33) | AAK1 | |
| SCHEMBL30006955 | 0.75 | CTSK (0.38) | KMT2ATRPA1TSHRHSD17B10CA1 | |
| SCHEMBL29163981 | 0.75 | CTSK (0.38) | KMT2ATRPA1TSHRHSD17B10CA1 | |
| SCHEMBL27783161 | 0.74 | SCN9A (0.34) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114872-B2 | Triazolyl aminopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8063212-B2 | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | ELI LILLY AND COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2125794-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-05-27 | — | — | US | disclosed |
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-04-01 | — | — | US | disclosed |
| EP-2155735-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2125794-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | Eli Lilly & Company (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008144222-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008076705-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, AURKC, BUB1B | KMT2A 723/4885TRPA1 2415/4885TSHR 3564/4885 |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | KMT2A 1133/4885TRPA1 3529/4885TSHR 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.